We analyze the transcriptome of baseline and on-therapy tumor biopsies from 101 patients
with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with …

The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …

Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients.
However, better pretreatment predictive biomarkers for ICI are still needed to help match …

Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb …

We concurrently examine the whole genome, transcriptome, methylome, and immune cell
infiltrates in baseline tumors from 77 patients with advanced cutaneous melanoma treated …

BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced
cancer, but many patients do not respond to treatment. The identification of robust …

In this study, we incorporate analyses of genome-wide sequence and structural alterations
with pre-and on-therapy transcriptomic and T cell repertoire features in immunotherapy …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Modulation of the immune system can produce anti-tumor responses in various cancer
types, including melanoma. Recently, immune checkpoint inhibitors (ICI), in single agent …

Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients,
but many patients derive no clinical benefit, and the molecular underpinnings of such …